Cyriac Roeding is a successful founder and investor, who is currently the CEO of Earli, a groundbreaking company on a mission to transform cancer into a manageable condition. Earli’s innovative gene therapy technology compels cancer cells to produce a synthetic, non-human biomarker, addressing the challenges of relying on naturally occurring biomarkers that cancer may not always provide.
A seasoned entrepreneur and investor, Cyriac has a track record of creating ventures that bridge the physical and digital worlds. He has invested in transformative companies like OpenAI and previously served as CEO of Shopkick, which was acquired for $250 million. Currently, his focus is on driving Earli’s success, with the company raising nearly $60 million from top-tier investors.
Get the latest insights from The Biotech Startups Podcast delivered straight to your inbox.
Subscribe to our twice-weekly newsletter for updates, news, and more—everything you need to stay ahead in biotech.
